- Home
- FMAO vs CAPR Comparison
FMAO vs CAPR Comparison
Compare FMAO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- CAPR
- Stock Information
- Founded
- FMAO 1897
- CAPR 2005
- Country
- FMAO United States
- CAPR United States
- Employees
- FMAO N/A
- CAPR N/A
- Industry
- FMAO Savings Institutions
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FMAO Finance
- CAPR Health Care
- Exchange
- FMAO Nasdaq
- CAPR Nasdaq
- Market Cap
- FMAO 344.8M
- CAPR 392.8M
- IPO Year
- FMAO N/A
- CAPR N/A
- Fundamental
- Price
- FMAO $22.99
- CAPR $13.89
- Analyst Decision
- FMAO Hold
- CAPR Strong Buy
- Analyst Count
- FMAO 1
- CAPR 7
- Target Price
- FMAO $26.00
- CAPR $39.29
- AVG Volume (30 Days)
- FMAO 19.1K
- CAPR 1.5M
- Earning Date
- FMAO 04-30-2025
- CAPR 05-12-2025
- Dividend Yield
- FMAO 3.85%
- CAPR N/A
- EPS Growth
- FMAO 13.49
- CAPR N/A
- EPS
- FMAO 1.90
- CAPR N/A
- Revenue
- FMAO $101,189,000.00
- CAPR $22,270,465.00
- Revenue This Year
- FMAO N/A
- CAPR $78.85
- Revenue Next Year
- FMAO $6.35
- CAPR $157.99
- P/E Ratio
- FMAO $12.13
- CAPR N/A
- Revenue Growth
- FMAO 5.74
- CAPR N/A
- 52 Week Low
- FMAO $19.95
- CAPR $3.52
- 52 Week High
- FMAO $34.15
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- FMAO 48.64
- CAPR 65.03
- Support Level
- FMAO $20.88
- CAPR $9.43
- Resistance Level
- FMAO $22.94
- CAPR $10.09
- Average True Range (ATR)
- FMAO 1.09
- CAPR 0.95
- MACD
- FMAO 0.11
- CAPR 0.54
- Stochastic Oscillator
- FMAO 61.16
- CAPR 96.98
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company for Farmers & Merchants Bank of Central California. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.